The Foundation for Dermatology Education to Host the 3rd Annual Live Revolutionizing Atopic Dermatitis (RAD) Conference - Saturday, December 11 - Monday, December 13, 2021
October 19, 2021 10:00 ET
|
The Foundation for Dermatology Education
CHICAGO, Oct. 19, 2021 (GLOBE NEWSWIRE) -- The 3rd Annual Live Revolutionizing Atopic Dermatitis (RAD) Conference will be held virtually this year from Saturday, December 11 - Monday, December 13...
ASLAN Pharmaceuticals Announces KOL Event Series to Discuss Atopic Dermatitis Treatment Landscape and ASLAN004
October 18, 2021 07:00 ET
|
ASLAN PHARMACEUTICALS LIMITED
- Management to host the first in a series of KOL webinars beginning Monday, October 25, 2021, at 10:00am ET - First patient in global, 300-patient Phase 2b study of ASLAN004 on track for enrolment...
Derm-Biome Pharmaceuticals, Inc. reports Positive Results from a Preclinical Study in Atopic Dermatitis: its new generation of compounds are significantly more effective than FDA-approved topical AD drug crisaborole
September 16, 2021 10:00 ET
|
Derm-Biome Pharmaceuticals, Inc
VANCOUVER, British Columbia, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals, Inc, a Vancouver based biopharmaceutical company focused on skin health and healthy ageing, is pleased to...
ASLAN Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update
August 06, 2021 07:00 ET
|
ASLAN PHARMACEUTICALS LIMITED
Recruitment completed in June for the expansion cohort of the Multiple Ascending Dose (MAD) trial of ASLAN004, underway for the treatment of patients with moderate-to-severe atopic dermatitis Topline,...
ASLAN Pharmaceuticals Announces Loan Facility Providing Up to $45 Million From K2 HealthVentures
July 13, 2021 07:00 ET
|
ASLAN PHARMACEUTICALS LIMITED
SINGAPORE, July 13, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the...
Derm-Biome Pharmaceuticals, Inc. files a US provisional patent for a new generation of natural product-based derivatives and their uses for treating chronic inflammatory skin conditions
June 29, 2021 09:30 ET
|
Derm-Biome Pharmaceuticals, Inc
VANCOUVER, British Columbia, June 29, 2021 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals, Inc, a private Vancouver based biopharmaceutical company focused on skin health and healthy ageing, is...
Derm-Biome Pharmaceuticals, Inc. adds skin disease and microbiome specialists Drs. Youwen Zhou and Andy Sham to Its Newly Created Scientific Advisory Board
June 02, 2021 08:00 ET
|
Derm-Biome Pharmaceuticals, Inc
VANCOUVER, British Columbia, June 02, 2021 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals, Inc, a Vancouver based preclinical biopharmaceutical company focused on skin health and healthy ageing,...
ASLAN Pharmaceuticals Announces Pricing of Public Offering of American Depositary Shares
March 03, 2021 00:42 ET
|
ASLAN PHARMACEUTICALS LIMITED
SINGAPORE, March 03, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the...
ASLAN Pharmaceuticals Announces Proposed Public Offering of American Depositary Shares
March 01, 2021 16:01 ET
|
ASLAN PHARMACEUTICALS LIMITED
SINGAPORE, March 01, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the...
ASLAN Pharmaceuticals Announces Positive Interim Data From the Multiple Ascending Dose Study of ASLAN004 in Atopic Dermatitis
March 01, 2021 06:00 ET
|
ASLAN PHARMACEUTICALS LIMITED
- 74% average reduction in EASI from baseline at therapeutic doses after 8 weeks. 89% of patients achieved EASI-50 and 56% achieved EASI-90 - Data supportive of ASLAN004’s potential as a novel,...